September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Identification of Genetic Variants Associated with Anti-VEGF Drug Response in Neovascular AMD Patients in the VIEW Trial
Author Affiliations & Notes
  • Lorah T Perlee
    Regeneron Pharmaceuticals, LLC, Tarrytown, New York, United States
  • Nancy Holekamp
    Prepose Vision Institute, Chesterfield, Missouri, United States
  • Footnotes
    Commercial Relationships   Lorah Perlee, Regeneron Pharmaceuticals, LLC (E); Nancy Holekamp, Regeneron Pharmaceuticals, LLC (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2639. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lorah T Perlee, Nancy Holekamp; Identification of Genetic Variants Associated with Anti-VEGF Drug Response in Neovascular AMD Patients in the VIEW Trial. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2639.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To identify genetic variants associated with anti-VEGF drug response as measured by visual acuity, anatomic outcomes and treatment frequency in the VIEW 1 study.

Methods : A genome wide association study (GWAS) was conducted on 362 VIEW 1 patients. DNA samples were genotyped using the Illumina Omni Express Exome Chip. Logistic regression with baseline values was performed to establish the association between genetic variants and efficacy variables. For each SNP, genotypes were coded according to an additive mode of inheritance. Variants associated with gaining ≥15 ETDRS letters at week 52, presence of intraretinal cystoid edema (fluid as measured by time domain optical coherence tomography (TD-OCT)) at week 52 and frequency of treatment at week 96 were evaluated.

Results : An X-chromosome SNP (rs2056688) revealed the highest association with anatomical outcome, demonstrating an odds ratio (OR) of 0.2578 and a point-wise association (p-value 7.27 x 10-7) with presence of intraretinal fluid at week 52. Four neighboring SNPs (rs5962084, rs5962087, rs5915722, rs5962095) revealed similar ORs (0.3151-0.3461) and point-wise associations (5.48 x 10 -6 – 8.59 x 10 -6). The rs2056688 SNP was located in a non-coding region, with the closest relevant functional gene (Protein Kinase X-Linked (PRK-X)) mapping ~400kb upstream of the putative variant. Additional SNPs with lower significance were found in association with proportion of patients with ≥15 ETDRS letters gains in vision at week 52 and frequency of treatment at week 96.

Conclusions : A GWAS in neovascular AMD patients undergoing anti-VEGF treatment in the VIEW 1 trial identified an association between a genetic variant and the presence of intraretinal fluid at week 52 as measured by TD-OCT. The variant was located at a position on the X chromosome near the gene for PRK-X, a serine/threonine protein kinase involved in angiogenesis. Given the relatively small number of samples evaluated in this study, the findings require validation in an independent dataset.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.